ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$34.93
+1.51%Year over year
Reported trailing growth
- Revenue
- -67.6%
- EBITDA
- +70.8%
- EBIT
- -15.2%
- EPS
- +45.7%
- Free cash flow
- +5.2%
- Operating cash flow
- +4.9%
Forward estimates
Based on analyst estimates
- Revenue
- +1226.5%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -36.0%
- EBITDA
- +60.9%
- EBIT
- -15.4%
- Net income
- -74.3%
- EPS
- -79.2%
- Free cash flow
- +10.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026